Platform & Technology » FlexFactory Biomanufacturing Platform » FlexFactory Scope, Scale & Application

FlexFactory Scope, Scale & Application

FlexFactory production trains are modular and configurable to meet a broad range of production needs, from cell culture through bulk drug substance. A typical FlexFactory train will feature two 2,000 liter XDR™ bioreactors. Assuming a 50% purification yield, an optimized process would produce bulk drug yields adequate for commercial production (see chart below).

Annual FlexFactory Production Output

Notes: Assumes 30 batches per year and 50% purification yield. Left axis is logarithmic scale.

The FlexFactory platform can effectively handle 70% of bioproducts, including products such as:

    Mammalian
    EPO, G-CSF, Cerazyme, Synagis, Interferon Beta, FSH, Factor VII/VIII/IX, TPA

    E. coli
    HGH, PTH, Hepatitis B Vaccine

    Vaccines
    MMR, Typhoid, Yellow Fever, Polio, Tetanus, Flu, Zoster

    Yeast
    Gardisil, Rototeq/Rotorex

    MAb's
    Rituxin, Lucentis, Xolair, Vectibix, Humira

FlexFactory will not effectively address products such as:

    Large scale MAb's >100 kg/yr
    Avastin, Herceptin, Remicade

    E coli
    insulins (tons/yr, high cell mass), interferon alpha's (low titers)

    Mammalian
    Enbrel (low titers)